Publication date: November 2026 Source: ESMO Real World Data and Digital Oncology, Volume 14, Supplement Author(s): A.H. Bryce, T.D. Ames, G. Roubaud, E. Castro Marcos, K.L. Ito, E. Scherrer, J. Baeck, J.F. O'Donnell, M. Price, K. Fizazi
325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC). // ESMO Real World Data and Digital Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949820126005072?dgcid=rss_sd_all
325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC). ESMO Real World Data and Digital Oncology. https://www.sciencedirect.com/science/article/pii/S2949820126005072?dgcid=rss_sd_all
“325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC).” ESMO Real World Data and Digital Oncology.
@article{article116746,
title = {325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC)},
journal = {ESMO Real World Data and Digital Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949820126005072?dgcid=rss_sd_all}
}